Table 4.
Clinical variables and EGFR/KRAS mutations associated with overall survival (multivariate analysis)
| HR (95% CI) | p-value | |
|---|---|---|
| Female vs. | 0.78 (0.67–0.90) | <0.001 |
| Male | 1 | |
|
| ||
| Age* | 1.15 (1.6–1.25) | 0.001 |
| 1 | ||
|
| ||
| KPS 80 –90% vs. | 0.54 (0.45–0.64) | <0.001 |
| ≤70% | 1 | |
|
| ||
| Current/Former vs. | 1.00 (0.85–1.18) | >0.99 |
| Never-Smoker | 1 | |
|
| ||
| EGFR (+) vs. | 0.62 (0.52–0.74) | <0.001 |
| EGFR wild-type | 1 | |
|
| ||
| KRAS (+) vs | 1.85 (1.47–2.32) | <0.001 |
| EGFR(+) | 1 | |
|
| ||
| KRAS (+) vs. | 1.21 (1.01–1.46) | 0.048 |
| EGFR/KRAS wild-type | 1 | |
*
the effect of age is constant until the age of 70 and linear thereafter. Therefore, HR=1.15 corresponds to an increase of 15% in the risk of death per 5 years of age, for patients 70 years and old.